End-stage renal disease: Endocrine aspects of treatment

Growth Hormone and IGF Research

Volumn 13, Issue SUPPL. A, 2003, Pages

  Johannsson, Gudmundur ^a   Ahlmén, Jarl ^b  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^b SKARABORG HOSPITAL   (Sweden)

Author keywords

Chronic renal failure; End stage renal disease; Growth hormone; Insulin like growth factor; Protein metabolism

Indexed keywords

ANABOLIC AGENT; ANDROGEN; DOPAMINE RECEPTOR STIMULATING AGENT; GROWTH HORMONE; PLACEBO; RECOMBINANT ERYTHROPOIETIN; SOMATOMEDIN C; TESTOSTERONE;

AGE DISTRIBUTION; ANEMIA; CHILDHOOD; CLINICAL TRIAL; DISEASE EXACERBATION; DRUG FATALITY; DRUG MECHANISM; ENDOCRINE DISEASE; FLUID RETENTION; GROWTH HORMONE DEFICIENCY; GROWTH RETARDATION; HEMODIALYSIS; HORMONAL THERAPY; HUMAN; HYPERGLYCEMIA; HYPERINSULINEMIA; HYPERPROLACTINEMIA; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; METABOLIC DISORDER; NONHUMAN; NUTRITIONAL STATUS; PERITONEAL DIALYSIS; PRIORITY JOURNAL; PROTEIN METABOLISM; REVIEW; SHORT STATURE; SURVIVAL RATE; TREATMENT OUTCOME; UREMIA; VIRILIZATION; WELLBEING;

EID: 0141832689     PISSN: 10966374     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1096-6374(03)00063-7     Document Type: Article

References (71)

1. S. Schön, Swedish registry for active treatment of uremia, Department of Nephrology, Skaraborgs Hospital, 1996.
2. A.R. Qureshi, A. Alvestrand, A. Danielsson, J.C. Divino-Filho, A. Gutierrez, B. Lindholm, J. Bergstrom, Factors predicting malnutrition in hemodialysis patients: a cross-sectional study, Kidney Int. 53 (1998) 773-782.
3. J.W. Eschbach, J.C. Egrie, M.R. Downing, J.K. Browne, J.W. Adamson, Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial, N. Engl. J. Med. 316 (1987) 73-78.
4. J.Z. Ma, J. Ebben, H. Xia, A.J. Collins, Hematocrit level and associated mortality in hemodialysis patients, J. Am. Soc. Nephrol. 10 (1999) 610-619.
5. P. Keshaviah, A.J. Collins, J.Z. Ma; D.N. Churchill, K.E. Thorpe, Survival comparison between hemodialysis and peritoneal dialysis based on matched doses of delivered therapy, J. Am. Soc. Nephrol. 13 (Suppl. 1) (2002) S48-S52.
6. A. Pinciaroli, Results of daily hemodialysis in Catanzaro: 12-year experience with 22 patients treated for more than one year, Home Hemodialysis Int. 2 (1998) 12-17.
7. S.G. Massry, M.J. Smogorzewski, S. Klahr, Metabolic and endocrine dysfunction in uremia, in: R.W. Schrier (Ed.), Diseases of the Kidney and Urinary Tract, Lippincott Williams & Wilkins, Philadelphia, PA, 2001, pp. 2815-2854.
8. D. Vimalachandra, J.C. Craig, C.T. Cowell, J.F. Knight, Growth hormone treatment in children with chronic renal failure: a meta-analysis of randomized controlled trials, J. Pediatr. 139 (2001) 560-567.
9. W.E. Mitch, B.J. Maroni, Factors causing malnutrition in patients with chronic uremia, Am. J. Kidney Dis. 33 (1999) 176-179.
10. W.F. Owen Jr., N.L. Lew, S.M. Yan Liu, E.G. Lowrie, J.M. Lazarus, The urea reduction ratio and serum albumin concentration as predictors of mortality in patients undergoing hemodialysis, N. Engl. J. Med. 329 (1993) 1001-1006.
11. C. Foulkes, D. Goldstein, M. Kelly, J. Hunt, Indications for the use of intradialytic parenteral nutrition in the malnourished hemodialysis patient, Renal Nutr. 1 (1991) 23-33.
12. W.E. Mitch, A.L. Goldberg, Mechanisms of muscle wasting. The role of the ubiquitin-proteasome pathway, N. Engl. J. Med. 335 (1996) 1897-1905.
13. N.J. Papadoyannikis, C.S. Stefanidis, M. McGeown, The effect of correction of metabolic acidosis on nitrogen and potassium balance of patients with chronic renal failure, Am. J. Clin. Nutr. 40 (1984) 623.
14. D. Reaich, S.M. Channon, C.M. Scrimgeour, S.E. Daley, R. Wilkinson, T.H. Goodship, Correction of acidosis in humans with CRF decreases protein degradation and amino acid oxidation, Am. J. Physiol. 265 (1993) E230.
15. V.S. Lim, D.M. Bier, M.J. Flanigan, S.T. Sum-Ping, The effect of hemodialysis on protein metabolism. A leucine kinetic study, J. Clin. Invest. 91 (1993) 2429.
16. E. Lofberg, P. Essen, M. McNurlan, J. Wernerman, P. Garlick, B. Anderstam, J. Bergstrom, A. Alvestrand, Effect of hemodialysis on protein synthesis, Clin. Nephrol. 54 (2000) 284-294.
17. T.A. Ikizler, L.B. Pupim, J.R. Brouillette, D.K. Levenhagen, K. Farmer, R.M. Hakim, P.J. Flakoll, Hemodialysis stimulates muscle and whole body protein loss and alters substrate oxidation, Am. J. Physiol. Endocrinol. Metab. 282 (2002) E107-E116.
18. J. Bergstrom, Nutrition and mortality in hemodialysis, J. Am. Soc. Nephrol. 6 (1996) 1329.
19. G. Garbotto, Muscle amino acid metabolism and the control of muscle protein turnover in patients with chronic renal failure, Nutrition 15 (1999) 145-155.
20. T.H. Goodship, W.E. Mitch, R.A. Hoerr, D.A. Wagner, T.I. Steinman, V.R. Young, Adaption to low-protein diet in renal failure: leucine turnover and nitrogen balance, J. Am. Soc. Nephrol. 1 (1990) 66-75.
21. 13C]leucine, Am. J. Clin. Nutr. 46 (1987) 778-783.
22. J.D. Veldhuis, A. Iranmanesh, M.J. Wilkowski, E. Samojlik, Neuroendocrine alterations in the somatotropic and lactotropic axes in uremic men, Eur. J. Endocrinol. 131 (1994) 489-498.
23. B. Tönshoff, J.D. Veldhuis, U. Heinrich, O. Mehls, Deconvolution analysis of spontaneous nocturnal growth hormone secretion in prepubertal children with preterminal chronic renal failure and with end-stage renal disease, Pediatr. Res. 37 (1995) 86-93.
24. R.V. Garcia-Mayor, A.J. Perez, A. Gandara, A. Andrade, F. Mallo, F.F. Casanueva, Metabolic clearance rate of biosynthetic growth hormone after endogenous growth hormone suppression with a somatostatin analogue in chronic renal failure patients and control subjects, Clin. Endocrinol. (Oxf.) 39 (1993) 337-343.
25. B.S. Tönshoff, S. Edén, E. Weiser, B. Carlsson, I.C. Robinson, W.F. Blum, O. Mehls, Reduced hepatic growth hormone (GH) receptor gene expression and increased plasma GH binding protein in experimental uremia, Kidney Int. 45 (1994) 1085-1092.
26. F. Schaefer, Y. Chen, T. Tsao, P. Nouri, R. Rabkin, Impaired JAK-STAT signal transduction contributes to growth hormone resistance in chronic uremia, J. Clin. Invest. 108 (2001) 467-475.
27. L.S. Phillips, A.C. Fusco, T.G. Unterman, F. del Greco, Somatomedin inhibitor in uremia, J. Clin. Endocrinol. Metab. 59 (1984) 764-774.
28. D. Powell, R. Rosenfeld, J. Sperry, B. Baker, R. Hintz, Serum concentrations of insulin-like growth factor (IGF)-1, IGF-2 and unsaturated somatomedin carrier proteins in children with chronic renal failure, Am. J. Kidney Dis. 10 (1987) 287-292.
29. R.H. Mah, Y.K. Pak, End-organ resistance to growth hormone and IGF-I in epiphyseal chondrocytes of rats with chronic renal failure, Kidney Int. 50 (1996) 400-406.
30. H. Ding, X.-L. Gao, R. Hirschberg, J.V. Vadgama, J.D. Kopple, Impaired action of insulin-like growth factor 1 on protein synthesis and degradation in skeletal muscle of rats with chronic renal failure, J. Clin. Invest. 97 (1996) 1064-1075.
31. P. Tollet-Egnell, A. Flores-Morales, A. Stavreus-Evers, L. Sahlin, G. Norstedt, Growth hormone regulation of SOCS-2, SOCS-3, and CIS mRNA expression in the rat, Endocrinology 140 (1999) 3693-3704.
32. P.R. Ram, D.J. Waxman, SOCS/CIS protein inhibition of growth hormone-stimulated STAT5 signalling by multiple mechanisms, J. Biol. Chem. 275 (1999) 35553-35561.
33. B. Tönshoff, O. Mehis, U. Heinrich, W.F. Blum, M.B. Ranke, A. Schauer, Growth-stimulating effects of recombinant human growth hormone in children with end-stage renal disease, J. Pediatr. 116 (1990) 561-566.
34. D. Haffner, F. Schaefer, R. Nissel, E. Wuhl, B. Tönshoff, O. Mehls, Effect of growth hormone treatment on adult height of children with chronic renal failure, N. Engl. J. Med. 343 (2000) 923-930.
35. R.C. Cuneo, F. Salomon, C.M. Wiles, R. Hesp, P.H. Sönksen, Growth hormone treatment in growth hormone-deficient adults. I. Effects on muscle mass and strength, J. Appl. Physiol. 70 (1991) 688-694.
36. G. Johannsson, G. Grimby, K. Stibrant Sunnerhagen, B.-Å. Bengtsson, Two years of growth hormone (GH) treatment increases isometric and isokinetic muscle strength in GH-deficient adults, J. Clin. Endocrinol. Metab. 82 (1997) 2877-2884.
37. J.A. Barreto-Filho, M.R. Alcantara, R. Salvatori, M.A. Barreto, A.C. Sousa, V. Bastos, A.H. Souza, R.M. Pereira, P.E. Clayton, M.S. Gill, M.H. Aguiar-Oliveira, Familial isolated growth hormone deficiency is associated with increased systolic blood pressure, central obesity, and dyslipidemia, J. Clin. Endocrinol. Metab. 87 (2002) 2018-2023.
38. L.K. Bachrach, R. Marcus, S.M. Ott, A.L. Rosenbloom, O. Vasconez, V. Martinez, A.L. Martinez, R.G. Rosenfeld, J. Guevara-Aguirre, Bone mineral, histomorphometry, and body composition in adults with growth hormone receptor deficiency, J. Bone Miner. Res. 13 (1998) 415-421.
39. D.M. Hoffman, R. Pallasser, M. Duncan, T.V. Nguyen, K.K. Ho, How is whole body protein turnover perturbed in growth hormone-deficient adults?, J. Clin. Endocrinol. Metab. 83 (1998) 4344-4349.
40. K.Y. Ho, J.D. Veldhuis, M.L. Johnson, R. Furlanetto, W.S. Evans, K.G. Alberti, M.O. Thorner, Fasting enhances growth hormone secretion and amplifies the complex rhythms of growth hormone secretion in man, J. Clin. Invest. 81 (1988) 968-975.
41. H. Norrelund, K.S. Nair, J.O. Jørgensen, J.S. Christiansen, N. Moller, The protein-retaining effects of growth hormone during fasting involve inhibition of muscle-protein breakdown, Diabetes 50 (2001) 96-104.
42. F.F. Horber, H.M. Marsh, M.W. Haymond, Differential effects of prednisone and growth hormone on fuel metabolism and insulin antagonism in humans, Diabetes 40 (1991) 141-149.
43. D.L. Russell-Jones, A.M. Umpleby, T.R. Hennessy, S.B. Bowes, F. Shojaee-Moradie, K.D. Hopkins, N.C. Jackson, J.M. Kelly, R.H. Jones, P.H. Sonksen, Use of a leucine clamp to demonstrate that IGF-I actively stimulates protein synthesis in normal humans, Am. J. Physiol. 267 (1994) E591-E598.
44. F. Salomon, R.C. Cuneo, R. Hesp, P.H. Sönksen, The effects of treatment with recombinant human growth hormone on body composition and metabolism in adults with growth hormone deficiency, N. Engl. J. Med. 321 (1989) 1797-1803.
45. D. Rudman, A.G. Feller, H.S. Nagraj, G.A. Gergans, P.Y. Lalitha, A.F. Goldberg, R.A. Schlenker, L. Cohn, I.W. Rudman, D.E. Mattson, Effects of human growth hormone in men over 60 years old, N. Engl. J. Med. 323 (1990) 1-6.
46. D. Chrysis, L.E. Underwood, Regulation of components of the ubiquitin system by insulin-like growth factor I and growth hormone in skeletal muscle of rats made catabolic with dexamethasone, Endocrinology 140 (1999) 5635-5641.
47. C.R. Edwards, P.M. Stewart, D. Burt, L. Brett, M.A. McIntyre, W.S. Sutanto, E.R. de Kloet, C. Monder, Localisation of 11 β-hydroxysteroid dehydrogenase - tissue specific protector of the mineralocorticoid receptor, Lancet 29 (1988) 986-989.
48. J.U. Weaver, L. Thaventhiran, K. Noonan, J.M. Burrin, N.F. Taylor, M.R. Norman, et al., The effect of growth hormone replacement on cortisol metabolism and glucocorticoid sensitivity in hypopituitary adults, Clin. Endocrinol. (Oxf.) 41 (1994) 639-648.
49. J.S. Moore, J.P. Monson, G. Kaltsas, P. Putignano, P.J. Wood, M.C. Sheppard, G.M. Besser, N.F. Taylor, P.M. Stewart, Modulation of 11 β-hydroxysteroid dehydrogenase isozymes by growth hormone and insulin-like growth factor: in vivo and in vitro studies, J. Clin. Endocrinol. Metab. 84 (1999) 4172-4177.
50. P.B. Jensen, T.B. Hansen, J. Frystyk, S.D. Ladefoged, F.B. Pedersen, J.S. Christiansen, Growth hormone, insulin-like growth factors and their binding proteins in adult hemodialysis patients treated with recombinant human growth hormone, Clin. Nephrol. 52 (1999) 103-109.
51. T.B. Hansen, J. Gram, P.B. Jensen, J.H. Kristiansen, B. Ekelund, J.S. Christiansen, F.B. Pedersen, Influence of growth hormone on whole body and regional soft tissue composition in adult patients on hemodialysis. A double-blind, randomized, placebo-controlled study, Clin. Nephrol. 53 (2000) 99-107.
52. T.A. Ikizler, R.L. Wingard, J.A. Breyer, G. Schulman, R.A. Parker, R.M. Hakim, Short-term effects of recombinant human growth hormone in CAPD patients, Kidney Int. 46 (1994) 1178-1183.
53. T.R. Ziegler, J.M. Lazarus, L.S. Young, R. Hakim, D.W. Wilmore, Effects of recombinant human growth hormone in adults receiving maintenance hemodialysis, J. Am. Soc. Nephrol. 2 (1991) 1130-1135.
54. G. Schulman, R. Wingard, R.L. Hutchinson, P. Lawrence, R.M. Hakim, The effects of recombinant human growth hormone and intradialytic parenteral nutrition in malnourished hemodialysis patients, Am. J. Kidney Dis. 21 (1993) 527-534.
55. G. Garibotto, A. Barreca, R. Russo, A. Sofia, P. Araghi, A. Cesarone, M. Malaspina, F. Fiorini, F. Minuto, A. Tizianello, Effects of recombinant human growth hormone on muscle protein turnover in malnourished hemodialysis patients, J. Clin. Invest. 99 (1997) 97-105.
56. D. Fouque, S.C. Peng, E. Shamir, J.D. Kopple, Recombinant human insulin-like growth factor-1 induces an anabolic response in malnourished CAPD patients, Kidney Int. 57 (2000) 646-654.
57. H. Kotzmann, N. Yilmaz, P. Lercher, et al., Differential effects of growth hormone therapy in malnourished hemodialysis patients, Kidney Int. 60 (2001) 1578-1585.
58. G. Johannsson, B.-Å. Bengtsson, J. Ahlmén, A double-blind, placebo-controlled trial of growth hormone treatment in elderly patients undergoing chronic haemodialysis: anabolic effect and functional improvement, Am. J. Kidney Dis. 33 (1999) 709-717.
59. E.G. Lowrie, N.L. Lew, Death risk in hemodialysis patients: the predictive value of commonly measured variables and an evaluation of death rate differences between facilities, Am. J. Kidney Dis. 15 (1990) 458-482.
60. M.V. Kaminski Jr., E.G. Lowrie, S.G. Rosenblatt, T. Haase, Malnutrition is lethal, diagnosable and treatable in ESRD patients, Transplant. Proc. 23 (1991) 1810-1815.
61. L.M. Kemoff, B.L. Pimstone, J. Solomon, J.F. Brock, The effect of hypophysectomy and growth hormone replacement on albumin synthesis and catabolism in the rat, Biochem. J. 124 (1971) 529-535.
62. J.J. Zachwieja, D.M. Bier, K.E. Yarasheski, Growth hormone administration in older adults: effects on albumin synthesis, Am. J. Physiol. 266 (1994) E840-E844.
63. A.M. Klidjian, K.J. Foster, R.M. Kammerling, A. Cooper, S.J. Karran, Relation of anthropodometric and dynamometric variables to serious postoperative complications, Br. Med. J. 281 (1980) 899-901.
64. J.-O. Johansson, G. Larson, M. Andersson, A. Elmgren, L. Hynsjo, A. Lindahl, P.A. Lundberg, O.G. Isaksson, S. Lindstedt, B.A. Bengtsson, Treatment of growth hormone-deficient adults with recombinant human growth hormone increases the concentration of growth hormone in the cerebrospinal fluid and affects neurotransmitters, Neuroendocrinology 61 (1995) 57-66.
65. P. Iglesias, J.J. Diez, M.J. Fernandez-Reyes, A. Aguilera, S. Burgues, J. Martinez-Ara, J.L. Miguel, A. Gomez-Pan, R. Selgas, Recombinant human growth hormone therapy in malnourished dialysis patients: a randomized controlled study, Am. J. Kidney Dis. 32 (1998) 454-463.
66. S. Holdsworth, R.C. Atkins, D.M. deKretser, The pituitary-testicular axis in men with chronic renal failure, N. Engl. J. Med. 296 (1977) 1245-1249.
67. B.F. Palmer, Sexual dysfunction in uremia, J. Am. Soc. Nephrol. 10 (1999) 1381-1388.
68. V.S. Lim, C. Henriquez, G. Sievertsen, L.A. Frohman, Ovarian function in chronic renal failure: evidence suggesting hypothalamic anovulation, Ann. Intern. Med. 93 (1980) 21-27.
69. N.T. Shahidi, Androgens and erythropoiesis, N. Engl. J. Med. 289 (1973) 72-80.
70. A.A. Ferrando, M. Sheffield-Moore, C.W. Yeckel, C. Gilkison, J. Jiang, A. Achacosa, S.A. Lieberman, K. Tipton, R.R. Wolfe, R.J. Urban, Testosterone administration to older men improves muscle function: molecular and physiological mechanisms, Am. J. Physiol. Endocrinol. Metab. 282 (2002) E601-E607.
71. C.J. Bagatell, W.J. Bremner, Androgens in men - uses and abuses, N. Engl. J. Med. 334 (1996) 707-714.